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Abstract
Context: Since ancient times diarrhoea has been a highly fatal disease and even today diarrhoea, the topic of this review, is a problem 
affecting millions of people around the world despite the efforts of governments and professionals from the medical area. Worldwide the 
most common cause of children’s death is diarrhoea.
Evidence Acquisition: Diarrhoea disorders generally appear with watery stools, sometimes mixed with blood, accompanied by 
abdominal pain, vomiting and fever. The symptoms depend on the content and distribution of body fluid, daily water requirements and 
physiological water loss in connection with age through sweating, urination and breathing, the degree of fluid and electrolyte loss in the 
liquid stool.
Results: Several effective interventions have been introduced as part of diarrhoea management in the last two decades such as oral 
rehydration solution, zinc supplementation, vitamin A supplementation and oral administration of antibiotics and vaccines. To reduce the 
mortality rate, control of safe drinking water, good sanitation and vaccination against typhoid and cholera are recommended, especially 
in high-risk populations. Probiotics have been proposed, after more than a half of century, as additional therapy in the treatment of acute 
diarrhoea. Several probiotic strains showed benefit in meta-analyses of randomised controlled trials.
Conclusions: Due to the high level of evidence available, the term “oral bacteriotherapy”, used for decades in the prevention and therapy 
of gastroenteritis in the growing age and adults, has expanded, but probiotics are acquiring significant scientific value based on the 
results from human trials. The future of probiotics depends on further explanation/elucidation of basic mechanisms, allowing scientists 
and physicians to maximize their health benefits.
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1. Context
The present paper is a review on diarrhoea, including 
pathogens that cause several types of diarrhoea, mor-
tality trend around the world and methods to detect 
the causative agents. The authors overviewed all the 
interventions to fight diarrhoea, such as oral rehydra-
tion therapy (ORS), zinc and vitamin supplementa-
tion, antibiotics, vaccine and probiotics in diarrhoea 
management.
1.1. Diarrhoea Definition
Diarrhoea is defined as stool emission with an excess 
weight of 200 grams per day and “pseudo diarrhoea” 
when faecal weight is < 200 g/24 hours (1, 2). Diar-
rhoea is an alteration of normal bowel movement, 
variation characterized by increased water content, 
volume and frequency of stools. Intestinal water bal-
ance results from a complex regulation involving in-
flammatory mediators, hormones, neuropeptides, in-
testinal wall integrity, enteric nervous and circulatory 
system efficiency (3).
1.2. Diarrhoea Epidemiology and Trends in Mortal-ity in WHO Regions
Worldwide, diarrhoea is the second most frequent 
fatal childhood disease after pneumonia, estimated 
to cause 1.34 million of children deaths. Different 
causes of death in children younger than five years 
vary over the world and WHO regions, although pneu-
monia and diarrhoea, remain the same, significantly 
increase where the health systems are inefficient (4, 5) 
(Table 1, Figure 1).
Of all deaths from diarrhoea, 78% of children live in the 
African and South-East Asian regions, which are dispro-
portionately loaded with infant and childhood HIV infec-
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tions (7). Diarrhoeal disease occurs more frequently in 
HIV-infected children and their consequences are worse. 
Administration of antiretroviral therapy (ART) and re-
storing the immune system are critical for preventing 
and treating diarrhoea in children affected by HIV (8). Re-
search on diarrhoea in children is a priority of WHO for 
achieving the United Nations’ Millennium Development 
Goal of reducing childhood mortality.
1.3. Types of Diarrhoea
Diarrhoea, from a clinical point of view, needs to be clas-
sified according to certain characteristics such as trends 
over time (acute or chronic) and faeces characteristics 
(watery, fatty, inflammatory, etc.) (3, 9).
Generally, episodes of diarrhoea can be classified into 
three categories including acute diarrhoea with pres-
ence of three or more watery stools within 24-hours, 
dysentery with bloody diarrhoea and mucous presence, 
persistent diarrhoea when episodes of diarrhoea last 
more than 14 days, while chronic diarrhoea when the 
episode lasts for more than a month (10, 11). Diarrhoea 
reflects higher water content in the stool, number of 
stools that may reach 20 or more per day, with defeca-
tion every 20 - 30 minutes.
1.4. Main Pathogens Responsible for Acute Diarrhoea
Diarrhoea is caused by infections, often spread from 
person-to-person or contaminated sources, water con-
taminated with human or animal faeces and other 
causes including poor personal hygiene, food conser-
vation in unhygienic conditions and malnutrition. Dy-
senteric cases often have no identifiable agent (12, 13).
1.4.1. Bacteria
Bacteria may be the causative pathogens (15 to 20%) 
including Salmonella spp., Campylobacter spp, and Esch-erichia coli. Bacteremia, sepsis, spreading to other organs 
represent systemic symptoms that complicate gastroin-
testinal infection, especially by Campylobacter, E. coli, Salmonella, Shigella, Aeromonas and Yersinia (Table 2). Clostridium difficile is a pathogen that causes uncompli-
cated antibiotic-associated diarrhoea and severe, possi-
bly fatal, antibiotic-associated colitis (14). Prevention is 
possible through infection control measures both clini-
cal and epidemiological (15). Many pathogenic serotypes 
of E. coli may cause different diarrhoea conditions. Some E. coli have evolved the ability to cause a wide spectrum 
of human diseases such as urinary tract infection, sepsis 
and/or meningitis and enteric/diarrhoeal disease. Also, Helicobacter pylori and Vibrio cholerae can be problemat-
ic, since they are pathogens that colonize the gastric mu-
cosa and cause acute inflammation, damaging the gas-
tric epithelium with serious consequences as superficial 
gastritis, chronic atrophic gastritis and gastric cancer.
1.4.2. Fungi
One of the major causes for morbidity and mortality 
in immunocompromised children are represented by 
the invasive fungal infections (IFIs), caused by Candida 
and Aspergillus species (16). Candida-induced diarrhoea 
is associated with prolonged secretory diarrhoea with 
abdominal pain and cramping, without blood, mucus, 
fever, nausea and vomiting (17).
1.4.3. Protozoan Parasites
Protozoan parasites, such as Cryptosporidium parvum/hominis, Cyclospora cayetanensis, Giardia lamblia 
and Isospora belli are infrequent causes of acute diar-
rhoea in healthy children (10 to 15%).
1.4.4. Parasites Helminths
Parasites Helminths affect adults and children world-
wide caused by predominantly rural settings, low per-
sonal hygiene, unsafe drinking water, poor sanitation, 
non-usage of toilets and the immune status of the child 
(18, 19).
1.4.5. Viruses
Adenovirus, Human Bocavirus, Human Astrovirus, 
Norovirus, Sapovirus and Rotavirus are known as the 
most common causative pathogens of gastroenteritis 
(50 to 70%) and compared to bacterial enteritis, usually 
have a better prognosis with a lower mortality, but they 
show a high morbidity. Toxin production, intestinal 
cells and tissue invasion, with consequent alteration of 
their function, are usually mechanisms of viral infec-
tious diarrhoea.
1.5. Diagnostic Methods
Many brief episodes of diarrhoea and gastroenteritis 
do not require any laboratory investigations and are 
managed without seeking professional advice. In par-
ticular circumstances, identification of the causative 
agent of infection is not possible only by history of 
disease, environmental risk factors, clinical signs and 
symptoms or characteristics of the faeces. Enteric infec-
tions diagnosed by analysis of bacterial cultures and 
microscopy detecting the bacterial enteric pathogen, 
ova and parasites has been the main method of diag-
nose for many years. Especially Campylobacter, Salmo-nella, Shigella, Vibrio, and Yersinia species are quite easily 
cultivated, isolated and finally identified. Isolation of 
cultured organisms is essential to determine sensitiv-
ity to antimicrobial agents for treatments and identify 
specific strains and their virulence factors (19). These 
traditional methods are time-consuming and since pa-
tients do not have a diagnosis for days, the risk of un-
treated infection and spreading of infection to other 
persons is high.
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Polymerase chain reaction (PCR) is a shorter, but 
more expensive assay with clinical applications, more 
sensitive and accurate using just few colonies from a 
patient with early-infections. With newer techniques 
available, laboratories are able to identify up to 70% of 
pathogens that cause acute diarrhoea. While, multi-
plex PCR allows simultaneous amplification and iden-
tification of multiple organisms in a single reaction 
(20, 21). Moreover, molecular techniques, as sensitive 
ELISA and latex agglutination, are required and very 
important for their highly sensitivity and specificity 
on infection detection in very small samples and in 
cases of multiple infections (19).
2. Evidences Acquisition
The patient generally develops watery stools, accord-
ing the pathogen type, sometimes mixed with blood, 
after an incubation period up to seven days, accompa-
nied by vomiting and fever (Tables 3 and 4). Symptoms 
depend on the content and distribution of body fluid 
(BF) by age, daily water requirements in connection 
with age, physiological water loss in connection with 
age through sweating, urination and breathing, the 
degree of fluid and electrolyte loss (sodium, chloride, 
potassium and bicarbonate) in the liquid stool. Clini-
cal estimation of the fluid deficit and dehydration, the 
most important symptom of acute gastroenteritis, oc-
curs when all these losses are not replaced adequately 
altering plasmatic volume and composition of intersti-
tial liquids and therefore homeostasis and metabolism 
of water.
Intra- and extracellular water, contained apparently 
completely in the lean mass, is the most important com-
ponent of the organism mostly in the first months of 
life when it represents approximately 80% of the body 
weight to be reduced to approach the value of adult as 
60% of the body weight, after the first year of life (2, 22). 
For this reason, daily water needs become more as child 
grows up. Dehydration is classified light if the loss of 
weight is below 3% in the first year of life and below 5% 
subsequently, moderate if it is 3%, (< 5%) -8% until 9% and 
serious if it is more than 9% with tachycardia, tubular 
necrosis to shock and coma.
However, vomiting and respiratory involvement are 
associated to a viral aetiology, in particular Norovirus 
and Rotavirus. When the infection affects children 
of a few months, diarrhoea tends to persist. High fe-
ver (> 40°C), presence of blood in faeces, abdominal 
pains, and central nervous system involvements are 
associated more frequently to one bacterial aetiology 
(Tables 3 and 4).
Serious dehydration (weight loss > 10%), neurological 
anomalies (lethargy, convulsions, etc.) intractable or bili-
ary vomit, inadequate oral rehydration and/or familiar 
assistance to domicile, or suspicion of a surgical patho-
logical picture, are necessary for hospitalization (1, 2).
3. Results
- Preventive and therapeutic aspects are as follows:
3.1. Vaccines
For years, there are vaccines against cholera, typhoid 
and lately, given the high frequency and severity of Rota-
virus infection, particularly during the first year of life, 
two orally administered Rotavirus vaccines, Rotarix™, 
which is a single-strain attenuated human Rotavirus 
vaccine, while RotaTeq is a multistrain bovine-human 
vaccine. They are safe and effective to prevent these en-
teric diseases with a 90% to 100% efficacy rate against 
severe Rotavirus in Europe, Latin America and North 
America, (23-25). Rotavirus vaccines prevent deaths of 
approximately 225000 children/year in the poorest 
countries and in the next 20 years more than 2.5 million 
would be protected by the infection (Figure 2) (25-27). 
Omenaca and coworkers (28) showed that Rotarix™ was 
well-tolerated and immunogenic; however, in pre-term 
children in Europe, safety and reactogenicity were equal 
to that of full-term infant.
3.2. Probiotics
Elia Metchnikoff (1845 - 1916) was the first to introduce 
“oral bacteriotherapy” using “good” and efficient bac-
teria present in fermented milk that prevent putrefac-
tion and aging. In his book “The prolongation of life. 
Optimistic studies”, Metchnikoff confirms that not all 
microbes are harmful to human health and suggests 
that useful microorganisms may replace the harmful 
one, modifying the intestinal flora. According to the 
FAO/WHO (29), probiotics are defined as “Live micro-
organisms, which confer a health benefit on the host 
when administered in adequate amounts”. They have 
been proposed in the prevention and as adjunctive 
therapy in the treatment of acute diarrhoea and other 
pathologic conditions. The probiotics effects on the 
intestinal microflora and antibacterial, immunostim-
ulatory and anti-inflammatory properties have been 
investigated in acute diarrhoea, travellers’ diarrhoea, 
antibiotic-associated diarrhoea (AAD), Clostridium dif-ficile gastroenteritis, chemo- or radiotherapy-induced 
diarrhoea, inflammatory bowel diseases, small bowel 
bacterial overgrowth and irritable bowel syndrome 
(IBS) (30-35).
3.2.1. Probiotics as Preventive Therapy
Several studies reported the use of probiotics (such as Lactobacillus GG) to prevent and treat acute diarrhoea 
with a significant decrease in the rate of diarrhoea in-
cidence (36). Invasive fungal infections are common 
and difficult to diagnose in infants; empirical treatment 
with antifungal therapy should be considered for those 
who fail to quickly respond to empirical antibacterial 
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preventive treatment. Risk factors to administer em-
pirical antifungal therapy include extreme prematurity, 
exposure to third-generation cephalosporins and pres-
ence of central venous catheters. To prevent gastrointes-
tinal colonization by Candida spp., the use of probiotics, L. rhamnosus and L. reuteri, appears to be effective with 
no associated adverse effects. They are effective in the 
protection from necrotizing enterocolitis (NEC), late-
onset sepsis and reducing abnormal neurological out-
comes in preterm neonates (37-39). L. reuteri probiotic 
strains have potential therapeutic value in the preven-
tion of experimental NEC. L. reuteri improves mucosal 
barrier and anti-inflammatory properties, feeding tol-
erance, probably due to its changes in intestinal flora, 
bowel habits and gastric motility (39). Administration 
of L. reuteri is always safe and well tolerated (39, 40). L. reuteri (DSM 17938) may prevent diarrhoea, especially in 
children with lower nutritional status (41).
A randomized controlled clinical trial on infants 
treated with probiotics showed no significant effect on 
growth and neurodevelopmental outcomes, but con-
firmed reduction in the incidence and severity of NEC 
(42). Another similar trial in newborns weighing below 
1500 grams showed potential benefits of probiotics for 
premature infants in reduction of NEC risk (43). Antibi-
otics, prescribed frequently in children, alter the micro-
bial balance within the gastrointestinal tract and cause 
associated diarrhoea (AAD).
Other studies on children and teenager under 18 years 
old receiving antibiotics, treated with two probiotic 
strains, Lactobacillus rhamnosus and/or Saccharomyces boulardii showed a protective effect of probiotics (44). 
Probiotics can prevent AAD by several mechanisms 
mostly by maintaining a healthy microflora. Another 
in vivo study of a probiotic formula containing Lactoba-cillus acidophilus CL1285 and Lactobacillus casei LBC80R 
(for prophylaxis of AAD and Clostridium difficile-associ-
ated diarrhoea) indicated a lower incidence of AAD and 
CDAD in patients treated with probiotic combination 
compared with the placebo group (45).
Also, recent randomized controlled trials (RCTs) of Lac-tobacillus, Bifidobacterium, Saccharomyces, Streptococcus, Enterococcus and/or Bacillus probiotic strains indicated a 
statistically significant association of probiotic adminis-
tration with reduction in AAD incidence.
3.2.2. Probiotics as Therapy
Acute diarrhoea is the most investigated field in the 
area of probiotic use, especially in children and many 
systematic reviews described the probiotics role. Probi-
otics demonstrated a good safety profile, significantly 
reduction of diarrhoea duration, reduction of stool 
frequency and reduction of hospitalization period 
(46). Using probiotics to treat diarrhoea is based on the 
modification of the intestinal microflora and it is well 
known that probiotics fight against enteric pathogens. 
Moreover, beneficial effects of probiotics in acute diar-
rhoea seem to be strain-specific, dose-dependent (> 1010 
CFU), significantly efficient in viral gastroenteritis and 
more evident when probiotics treatment is initiated at 
the beginning of disease (46).
A recent meta-analysis designed to determine whether 
some probiotics (11 probiotics species and species mix-
tures) are beneficial, showed a positive effect in preven-
tion and/or treatment of Infectious diarrhoea, Antibiotic 
Associated Diarrhoea, Clostridium difficile disease, Helico-bacter pylori infection, Irritable Bowel Syndrome and Pou-
chitis, but did not show significant effects in Travellers’ 
Diarrhoea and Necrotizing Enterocolitis.
Probiotic strains with demonstrated beneficial effects, 
decreasing the frequency of diarrhoeal infections and in-
creasing production of Rotavirus-specific antibodies are L. reuteri, L. rhamnosus GG, L. casei Shirota, L. acidophilus, Bi-fidobacterium animalis ssp., B. lactis BB-12, E. coli, Enterococ-cus faecium SF68 and Saccharomyces boulardii (33). These 
probiotics showed a significantly reducing incidence of 
acute diarrhoea when the treatment dose reaches the 
concentration of 2 × 108 CFU/die (35).
Other studies showed that both probiotic strains L. re-uteri DSM 17938 and L. reuteri ATCC PTA 6475 decreased 
concentrations of proinflammatory cytokines, enhanced 
intestinal microbiome richness, enterocyte prolifera-
tion, villus repopulation and virus-specific antibodies. All 
these facts contribute to a better nutritional status and 
reduce diarrhoea duration (47).
All these studies and trials may provide understandings 
into the clinical application of probiotics, but it is impor-
tant to elucidate the mechanisms of probiotics to maxi-
mize their health benefits (48).
3.3. Oral Rehydration Therapy (ORT)
Rehydration therapy, either intravenous or oral, is 
a choice treatment for fluid and electrolyte losses 
caused by diarrhoea, decreasing the number of deaths 
to less than 1% from 25 - 50% (49). Oral rehydration 
therapy (ORT) and in particular oral rehydration solu-
tion (ORS) are the standard therapies for an efficient 
and cost-effective management of acute gastroenteri-
tis. ORS has several advantages, such as reduced need 
of intravenous infusions, less stool output and less 
vomiting. New formulations with a better taste and/
or efficacy of oral rehydration solution (ORS) are avail-
able (Table 5) (50).
Among all oral solutions, the ideal one has a low os-
molarity (210 - 250 mOsm/L) and a sodium content of 50 
– 60 mmol/L to avoid high levels of serum sodium. The 
low osmolarity oral rehydration solution with reduced 
concentrations of sodium and glucose, (≤ 270 mOsm/L) 
and zinc supplementation is associated with fewer un-
scheduled intravenous fluid infusions, lower stool vol-
ume and less acetone vomiting than the standard ORS 
and is recommended in treating adults and children 
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(1, 51). The solution should be administered frequently 
and in small amounts to prevent vomiting, 50 – 100 mL/
Kg in the first four hours (11, 52).
3.4. Inhibitors of Intestinal Secretions
Several measures have been investigated as adjunct 
therapy to ORS including a variety of non-specific anti-
diarrhoeal agents, anti-motility agents and anti-secretory 
agents such as racecadotril (or acetorphan). The Ameri-
can Academy of Paediatrics and Centres for Disease Con-
trol and Prevention published practice parameters for 
management of acute gastroenteritis, but studies have 
shown ORS underuse globally (53).
In patients with various forms of acute diarrhoea, af-
ter oral administration, racecadotril is rapidly convert-
ed into thiorphan, acting on the enkephalins, which 
inhibits pathologic (but not basal) secretion of water 
and electrolyte from the gut, without modifying the 
gastrointestinal transit time and motility. In general, 
racecadotril has been reported to have a good safety 
profile as side effects were similar with placebo and no 
serious events were observed in all trials in adults and 
children (53, 54).
Several guidelines on children with acute diarrhoea 
recommend a treatment with oral rehydration en-
riched/supplemented with racecadotril. The cost util-
ity of racecadotril with oral rehydration solution (ORS) 
for the treatment of acute watery diarrhoea (AWD) was 
studied on children younger than five years showing that 
racecadotril is more effective as adjuvant therapy and 
less costly compared to ORS (54, 55).
3.5. Antibiotic Treatment
3.5.1. Bacterial Infection
Since most of diarrhoea causes are not able to be iden-
tified, empiric antibiotic treatment gives a harmful 
eradication of normal flora, which increases the risks of 
diarrhoea and other fatal infections and emergence of 
multidrug resistant microorganisms (3, 13). Antibiotic 
therapy is not indicated but is helpful for children with 
bloody diarrhoea (most likely shigellosis), severe dehy-
dration (like suspected cholera cases) and non-intestinal 
associated infections (like pneumonia).Aeromonas spp.: pathogenicity can be influenced by the 
immune status of infected child, various virulence fac-
tors and production of β-lactamases, which induces resis-
tance to penicillin and first-generation cephalosporins 
(cefotaxime) (56-58).Campylobacter infections may be treated with ampicil-
lin and azithromycin when patient has severe symptoms 
(59). Clostridium difficile (CDI) can be recovered from new-
borns as early as the first week of life and 71% of children 
below 12 months of age are colonized without traditional 
risk factors as antibiotic use and health-care exposure. 
Recent studies suggest discontinuous treatments of the 
offending antibiotic, such as metronidazole, linezolid 
and vancomycin.
Diarrhoeagenic Escherichia coli (DEC) usually heals it-
self contrary to common E. coli gastroenteritis within a 
couple of days, especially preventing dehydration. It is 
therefore appropriate to drink in small sips, to prevent 
vomiting, water and/or sports drinks in proportion to the 
amount of liquid stools within 24 hours, eat small meals 
throughout the day instead of three large meals, with 
some salty foods and potassium-rich foods such as ba-
nanas and potatoes. Antibiotics are contraindicated and 
should be prescribed only on specific clinical and labora-
tory indications.
Early empirical therapy of Enterotoxigenic E. coli 
(ETEC) with probiotics, antibacterial drugs (rifaximin, 
fluoroquinolone, azithromycin) decreases the disease 
duration.Helicobacter pylori causes diarrhoea, but also gastri-
tis, peptic ulcer and gastric cancer. Eradication of the 
pathogen includes a therapy for 7 - 14 days with lanso-
prazole, omeprazole, pantoprazole, rabeprazole, dex-
lansoprazole or esomeprazole to decrease the stomach 
production of acid (60).
In cases of Salmonella spp. infection, several trials sug-
gest that a treatment with antibiotics, such as ampicil-
lin, amoxicillin, cefixime, azithromycin or cotrimoxazole 
could be appropriate (59).Shigella spp. cause an invasive gastroenteritis and are 
relatively common in children. Symptoms are mild and 
self-limiting. In more severe cases, diverse antibiotics 
(ciprofloxacin, ampicillin, cotrimoxazole, nalidixic acid, 
ceftriaxone and azithromycin) are recommended as the 
pathogens have regional differences in sensitivity.
Without treatment, severe infection of Vibrio cholerae 
has a mortality rate of 30 - 50%, but by an effective thera-
py mortality can decrease reaching 0.2%. The therapy in-
cludes ampicillin, ceftriaxone, ciprofloxacin, tetracycline 
and trimethoprim.
Infections by Yersinia enterocolitica resolves spontane-
ously within two weeks. Y. enterocolitica is sensitive to 
meropenem, ceftriaxone, ciprofloxacin, ceftazidime and 
amikacin, while is resistant to ampicillin (61).
The high antibiotic resistance registered worldwide el-
evates a wide discussion on randomly and inappropriate 
use of antibiotics and surveillance of preponderance of 
the main pathogens and their resistance.
3.5.2. Fungal Infection
Recently three new antifungals drugs, anidulafungin, 
caspofungin and micafungin, have been introduced, 
with advantages on fluconazole and amphotericin B, 
which might better fit with the needs of paediatric pa-
tient, neonate and preterm with invasive candidiasis 
and/or diarrhoea.
Micafungin has fungicidal activity against Candida 
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species, invasive candidiasis, diarrhoea, necrotizing 
enterocolitis and lateonset sepsis; the recommended 
dosage in children is 2 mg/kg/day (100 mg/day if > 40 
kg body weight) (62). Caspofungin (1 mg/kg of body 
weight/day), as micafungin, has similar activities 
against natively Candida strains resistant to flucon-
azole, invasive candidiasis and diarrhoea and are well 
tolerated also in neonates (63).
3.5.3. Parasitic-Protozoan 
The most common treatments for Cryptosporidium parvum/hominis infections are paromomycin, azithro-
mycin and nitazoxanide (NTZ) (64). The therapy for Cy-clospora cayetanensis infections is constituted by TMP-
SMX (5 - 25 mg/kg of body weight/day) or ciprofloxacin 
as an alternative therapy (65). Giardia lamblia, a diarrhea-
genic protozoan pathogen, is commonly treated with 
metronidazole (MTZ), tinidazole, albendazole, auranofin 
or NTZ, reducing the duration of diarrhoea (Table 6) (66, 
67). Diarrhoea caused by Entamoeba histolytica can be 
treated with metronidazole and other nitroimidazoles, 
supplemented with luminal amebicides (paramomycin). 
A more recent therapeutic advance is nitazoxanide de-
creasing diarrhoeal illness period.
The World Health Organization classified auranofin as 
an antirheumatic agent, identified as 10 times more po-
tent than metronidazole, in culture and a mouse model, 
on Entamoeba histolytica. Auranofin could represent a 
promising therapy for amebiasis (64).
3.5.4. Parasitic-Helmints Nematodes
Parasitic-helmints nematodes do not exert signifi-
cantly negative effects on the growth and education of 
children. Strongyloides stercoralis, which causes several 
diseases, may be eradicated by Ivermectin therapy (68).
While to treat Trichuris trichiura, mebendazole demon-
strates a good efficacy, since albendazole shows a low 
effect (69, 70). 
Table 1. Distribution of Deaths From Diarrhoea in Children (Aged 
Less Than 5 Years) by Region (Modified Rudan et al. 2008 (6))
Regions
Deaths
Millions Percentage
Africa 4.396 16
America 0.439 12
Eastern-Mediter-
ranean 1.409 17
Europe 0.263 13
Southeast Asia 3.070 18
Western Pacific 1.020 17
3.6. Alternative Therapies
3.6.1. Zinc
Zinc represents a new intervention for treating diarrhoea, 
which activates transcription factor NF-κB and modulates 
host defence and since its deficiency is associated with 
high inflammation and bad outcomes in fighting bacterial 
infections (71). Several studies showed that 10 – 20 mg zinc 
per day for 10 - 14 days significantly reduces the gravity and 
duration of diarrhoea in small children (72, 73).
Some studies found that supplementation of ORS with 
zinc and probiotics limits diarrhoea duration. The expla-
nations for this differential effect of zinc benefits only in 
children from developing countries might be due to the 
fact that zinc deficiency (secondary to malnutrition, caus-
ing decreased absorption of zinc, diarrhoeal disease itself 
causing excess zinc loss in stool, dietary factors causing 
low intake due to poor socio-economic status, etc.) is asso-
ciated with impaired water and electrolyte absorption, in 
children from developed countries (74).
3.6.2. Vitamin A
It is well known that the relative risk of death from diar-
rhoea increases twice in children with vitamin A deficiency. 
It has been demonstrated that a daily dose of vitamin A (400 
µg) for newborns is effective in reduction of mortality (75).
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Table 2. Main Pathogens Responsible for Acute Diarrhoeaa
Responsible for 20% of All Types of Diarrhoea
Bacteria
Aeromonas hydrophila Aerobic bacillus Gram-negative. which is likely but not universally, accepted causes of acute diarrhoea.
Campylobacter jejuni Persist a long-time in the intestine, cause recurrent diarrhoea and often the traveller’s diarrhoea with Salmonella is the principal cause of diarrhoea.
Clostridium difficile Saprophyte that give virulence as a result of antibiotic or immunosuppressive therapy.
Escherichia coli EAEC (enteroaggregative, 0104: H4 serogroup, gained foreign genetic material including Shiga toxin and aggregative-adherence fimbriae), EHEC (enterohaemorrhagic, 0157: H7 serogroup, in 10% of young 
people, leads to hemolytic-uremic syndrome CHUS) by Shiga-like-2 toxin), EIEC (enteroinvasive), EPEC 
(enteropathogenic), ETEC (enterotoxigenic).
Salmonella species S. choleraesuis, S. enteritidis (with more than 1000 strains responsible for minor Salmonella diseases).
Shigella species S. dysenteriae, S. sonnei, S. flexneri, S. bovdii release Shiga toxin, which is cytotoxic and neurotoxic that 
causes watery diarrhoea may progress to bloody diarrhoe.
Vibrio cholerae Often fatal for the rapid and severe depletion of volume. Today much less frequent, but is a potential 
for epidemic spread.
Yersinia enterocolitica Can cause chronic forms with abdominal pain, like appendicitis, with or without blood.
Fungi Responsible for 1% of all diarrhoea.
Candidia spp. Often after antibiotic or immunosuppressive therapy or in preterm infants or in neonate.
Parasites-Protozoa Responsible for 9% of all diarrhoea.
Cryptosporidium parvum/hominis Encrypt sporidiosi. Frequently asymptomatic. Affects small intestines causing mucosal damage and malabsorption.
Cyclospora Frequent watery stools, which can be accompanied by fever and a relapsing course. Gastrointestinal 
tract symptoms are followed by muscle inflammation and periorbital edema.
Entamoeba histolytica Amoebiasis. It invades the large intestine and causes bloody diarrhoea.
Giardia intestinalis Giardiasis. It affects the small bowel and leads to acute or persistent diarrhoea with malabsorption 
and bloating.
Parasites-helmints
Strongyloides stercoralis Chronic or watery diarrhoea, abdominal cramping, failure to thrive, cachexia; fatal hyperinfection if 
immunity is suppressed.
Trichuris trichiura Inflammatory damage to mucosa, diarrhoea and bloody diarrhoea, iron-deficiency anemia.
Viruses Responsible for 70% of all diarrhoea.
Adenoviridae (DNA virus) Adenovirus serotypes 40 and 41, III viral pathogen.
Astroviridae (DNA virus) Human Astrovirus, frequent severe vomit ++++
Parvoviridae (DNA virus) Bocavirus involved in many clinical manifestations, including gastroenteritis Dependovirus.
Calicivirides (RNA virus)
Noroviruses, the II pathogen after Rotavirus (4 - 19%) vomit +++ and diarrhoea Human Sapovirus, spo-
radic cases mainly in young children aged 5 years; transmission by the faecal-oral route.
Reoviridae (RNA virus)
Orthoreovirus, sporadic cases; respiratory infections Rotavirus A, B, C, responsible for 30 - 60% of all 
viral diarrhoea and diarrhoea hospitalizations. It also propagates by air. Vomit +++
aIntensity of vomit presented as +, slight; ++, mild; +++, moderate; ++++, severe.
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Table 3. Clinical Features of Infection With Selected Diarrhoeal Pathogens (Modified WGO 2008 (11))a
Pathogens
Clinical Features
Abdominal Pain Bloody Stool Faecal Evidence of Inflammation Fever
Heme-Positive 
Stool
Vomiting and/or 
Nausea
Campylobacter O V O
Clostridium difficile O O O O
Shiga toxin-producing 
E. coli N A O
Salmonella O V O
Shigella O V
Vibrio V N V V V V
Yersinia O O O O
Candida O N V
Cryptosporidium V O V O
Cyclospora V V O
Entamoeba histolytica O V V O V
Giardia O N V
Norovirus V V O
aCommon: O-occurs, V-variable. Not common: A-atypical, N-often not.
Table 4. Microorganisms and Frequency of Symptoms
Microorganisms Incubation Duration Vomiting Fever Abdominal Pain
BacteriaAeromonas species None 0 - 2 a +/- +/- NoBacillus species 1 - 16 b 1 - 2 c Yes No YesCampylobacter species 2 - 4 c 5 - 7 c No Yes YesClostridium difficile Variable Variable No Few FewC. perfringens 0 - 1 c 1 c Mild No Yes
Enterohemorrhagic E. coli 1 - 8 c 3 – 6 c No +/- Yes
Enterotoxigenic E. coli 1 – 3 c 3 – 5 c Yes Low YesListeria species 20 b 2 c Few Yes +/-Plesiomonas species None 0 - 2 a +/- +/- +/-Salmonella species 0 - 3 c 2 - 7 c Yes Yes YesShigella species 0 - 2 c 2 - 7 c No High YesStaphilococcus aureus 2 - 6 b 1 c Yes No YesVibrio species 0 - 1 c 5 - 7 c Yes No YesYersinia enterocolitica 0 - 6 c 1 - 46 c Yes Yes Yes
FungiCandida 0 - 1 c 1 c No No Few
ParasitesCyclospora 1 a Up to 2 d +/- Yes YesGiardia 10 c 10 - 14 c No No Yes
Viruses
Norovirus 12 - 48 b 2 - 5 c Yes Yes Yes
Rotavirus 2 - 4 c Variable Yes Yes Yes
aValues unit is week.
bValues unit is hour.
cValues unit is day.
dValues unit is month.
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Table 5. Rehydration Compounds on the Worldwide Market (Modified Caramia et al. 2009 (9))a
Glucose 
mmol/L Na mEq/L K mEq/L Cl mEq/L
HCO3 o Citrate mEq/L mOsm/L Kcal/L Aroma Probiotics
ESPGHAN 
(1989/97) 74 - 111 60 20 > 25 20 200 - 250 52 - 80 No No
WHO 
(1984/2002) 110/75 90/75 20 80 30/C.8 - 12 311/245 80 No No
AMESOL 111 90 20 60 9 245 80 Lemon No
DICODRAL 111 30 20 40 10 211 80 No No
DICODRAL 60 90 60 20 37 14 citrate 211 80 Banana No
DICODRAL 
FORTE 111 90 20 80 30 331 80 No No
FLORIDRAL 83 60 20 37 14 citrate 214 80 Banana LGG CFU = 
5 × 109
GES 60 108 60 20 50 14 citrate 270 80 No No
IDRATON 245 75 75 20 65 10 citrate 245 79.1 Orange No
IDRAVITA 120 60 20 50 10 citrate 230 80 Banana No
PREREID® 77 50 20 40 10 200 79.35 Citrus No
PREREID® 
LIQUID 1.91 50 20 57 66 230 80 Citrus No
REIDRAX 75 60 20 60 10 citrate 225 60.8 No No
REUTERIN 
BRICK 61 58.5 19.2 44.3 230 45 Apricot
L. reuteri 
DSM 17938 
CFU = 108
REUTERIN IDRO 83 61 20 46 11 220 60 No
L. reuteri 
DSM 17938 
CFU = 108
Home solution
Water 1 
liter, Sugar 
1 spoon (19 
g), Salt 1 
spoon (3 g), 
Bicarbonate 
one needle 
(0, 5 g).
aCFU, colony forming units; C, chloride; ESPGHAN, European Society of Paediatric Gastroenterology, HCO, Hepatology and, Nutrition; HCO3, 
bicarbonate; K, potassium; L, liter; LGG, Lactobacillus rhamnosus GG; L. reuteri, Lactobacillus reuteri; Na, sodium; WHO, World Health Organization.
Table 6. Antibiotics Used to Treat Specific Causes of Diarrhoea
Pathogen Antibiotic/s of Choice Antibiotic/s Alternative
Aeromonas hydrophila Ciprofloxacin Meropenem
Campylobacter Azithromycin Erythromycin
Clostridium difficile Metronidazole or Vancomycin Linezolid or fidaxomicin
Cholera Doxycycline or Tetracycline Furazolidone or Erythromycin
E. coli EAEC; E. coli EHEC; E. coli EIEC; E. 
coli EPEC; E. coli ETEC
Cephalosporin of III generation or Cipro-
floxacin or Rifaximin
Colistin or Azithromycin or Meropenem
Salmonella Ceftriaxone or Ampicillin Amoxicillin or Cephalosporin of III gen-
eration or Fluoroquinolones
Shigella dysentery Ampicillin or Ciprofloxacin Nalidixic Acid or Fluoroquinolones
Candida Fluconazole Amphotericin B
Amoebiasis Metronidazole or Tinidazole Paromomycin
Cryptosporidium, Cyclospora cayeta-
nensis Nitazoxanide, Cotrimoxazole Paromomycin and azithromycin
Giardiasis Tinidazole or tazoxanide Metronidazole
Isospora belli Cotrimoxazole Pirimetamina
Strongyloides stercoralis Thiabendazole Albendazole or Ivermectin
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4. Conclusions
UNICEF and WHO published an exhaustive report on 
diarrhoea in 2009. This report includes a key package on 
diarrhoea prevention and treatments to reduce diarrhoea 
morbidity and mortality. The recommendations include 
improved access to safe water, promotion of sanitation, vi-
tamin A and zinc supplementation, promotion of breast-
feeding and treatment with ORS (76). A scale-up scenario 
using data from 2010 presumed a linear increase from the 
baseline coverage year (2010) through 2015, allowing to 
determinate total number and percentage of diarrhoeal 
deaths (Figure 3). The results of this modelling application 
demonstrate that diarrhoeal deaths might be decreased 
by at least 78% until 2015 with current available therapies.
Intensive promotion of ORS use, zinc and vitamin A sup-
plementation and training health staff can be successful 
in reducing diarrhoeal deaths (76). On the other hand, 
fortifying and stimulating the community management 
of diarrhoea, superfluous and unnecessary antibiotic use 
can be significantly reduced.
It was shown that probiotics can be an effective supple-
ment for diarrhoea management. It is very important and 
essential to prescribe strains documented to be effective, 
such as L. reuteri, Lactobacillus GG, L. acidophilus, L. bulgaricus 
and Saccharomyces boulardii. Moreover, the concentration 
has a significant relevance and it was demonstrated that a 
dose of 1010 CFU/day is effective, reducing diarrhoea dura-
tion and spreading (78, 79). Furthermore, probiotic strain 
alone or in combination (2 or more strains) provides sig-
nificant protective effects against intestinal disorders (80).
Many studies showed that probiotics significantly reduce the 
risk of acute diarrhoea, antibiotic-associated diarrhoea and 
traveller’s diarrhoea. Regarding different described approach-
es to control intestinal disorders, as diarrhoea, the effects ex-
erted by different probiotics give promising alternatives, so 
clinicians should advise those probiotic strains proven to be 
efficacious in relevant patient groups and encourage further 
clinical research studies to define its proper place in the man-
agement of several gastrointestinal tract disorders.
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Figure 3. Trends in Percentage and Number of Diarrheal Deaths, Under 
Ambitious (●) and Universal (■) Scale-up Plans (Modified Fischer Walker 
et al. 2011 (77))
In conclusion, there are several tools to manage and re-
duce diarrhoea incidence such as adopting practices to 
decrease risk factors, using feeding guidelines (including 
breastfeeding) and probiotics.
Footnote
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